Precigen (PGEN) Cash & Equivalents (2011 - 2026)

Precigen (PGEN) has 16 years of Cash & Equivalents data on file, last reported at $7.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.5 million, up 23.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (up 23.47% YoY), and the FY2025 annual result was $30.2 million, up 2.43% from the prior year.
• Cash & Equivalents retreated to $7.5 million in Q1 2026 per PGEN's latest filing, from $30.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $43.8 million in Q2 2022 and troughed at $4.9 million in Q4 2022.
• A 5-year average of $17.3 million and a median of $13.8 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 86.66% in 2022, then surged 289.51% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $4.9 million in 2022, then surged by 55.99% to $7.6 million in 2023, then surged by 289.51% to $29.5 million in 2024, then grew by 2.43% to $30.2 million in 2025, then plunged by 75.26% to $7.5 million in 2026.
• Business Quant data shows PGEN's Cash & Equivalents at $7.5 million in Q1 2026, $30.2 million in Q4 2025, and $14.3 million in Q3 2025.